1. Scrip
  2. >>Business

Biocon Sees Recovery In Biosimilars, Scope To Address Affordability In US

Mylan Partnership Bears Fruit

 
• By Anju Ghangurde

Biocon’s biosimilars business sees bounce-back in first quarter of fiscal 2021, with the US business witnessing gradually improving demand. The Indian company also sees potential for improved affordability in the US.

Shutter_M/Shutterstock.com
Biocon Biologics Regains Momentum In First Quarter • Source: Shutterstock

Biocon, Ltd.’s biosimilars business appears to have regained some momentum in the first quarter of fiscal 2021, after a tough previous quarter impacted by COVID-19-related challenges. The Indian firm is confident of a continued uptick in the US, where it sees headroom for greater affordability for biosimilars.

Revenues in the biosimilars segment rose by 19% to INR6.92bn ($92.6m) in the three-month period ended 30 June, led by robust gains across the company’s "most of the world" (MoW) markets, steady traction of key biosimilars in the US and Europe and also a “spillover” of revenues from the previous quarter

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

More from Scrip

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.